MannKind (MNKD) Secures Pediatric Afrezza Grant, Is The Stock Still Cheap?

Simply Wall St.06-26

MannKind (MNKD) is back in focus after securing a Breakthrough T1D grant to support its INHALE-1 pediatric trial of Afrezza inhaled insulin in newly diagnosed type 1 diabetes patients. See our latest ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646544233?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-26 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646544233","market":"hk","top_or_hot":-1,"title":"MannKind (MNKD) Secures Pediatric Afrezza Grant, Is The Stock Still Cheap?","media":"Simply Wall St.","content":"<div>\n<p>MannKind (MNKD) is back in focus after securing a Breakthrough T1D grant to support its INHALE-1 pediatric trial of Afrezza inhaled insulin in newly diagnosed type 1 diabetes patients. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-secures-pediatric-afrezza-grant-is-the-stock-s\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind (MNKD) Secures Pediatric Afrezza Grant, Is The Stock Still Cheap?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind (MNKD) Secures Pediatric Afrezza Grant, Is The Stock Still Cheap?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-26 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-secures-pediatric-afrezza-grant-is-the-stock-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MannKind (MNKD) is back in focus after securing a Breakthrough T1D grant to support its INHALE-1 pediatric trial of Afrezza inhaled insulin in newly diagnosed type 1 diabetes patients. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-secures-pediatric-afrezza-grant-is-the-stock-s\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-secures-pediatric-afrezza-grant-is-the-stock-s","article_id":"2646544233","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/mannkind-mnkd-secures-pediatric-afrezza-grant-is-the-stock-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646544233","pubTimestamp":1782473134,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"MannKind (MNKD) is back in focus after securing a Breakthrough T1D grant to support its INHALE-1 pediatric trial of Afrezza inhaled insulin in newly diagnosed type 1 diabetes patients.\nSee our latest analysis for MannKind.\nAgainst this grant backdrop, MannKind’s share price has shown strong recent momentum, with a 30 day share price return of 11.33% and a 90 day share price return of 72.37%, even though the year to date share price return is down 29.82% and the 1 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗","BK4584":"避孕概念","BK4139":"生物科技"},"translate_title":"MannKind(MNKD)获得儿科Afrezza资助，股票还便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1.5},"content_text":"MannKind (MNKD) is back in focus after securing a Breakthrough T1D grant to support its INHALE-1 pediatric trial of Afrezza inhaled insulin in newly diagnosed type 1 diabetes patients. See our latest analysis for MannKind. Against this grant backdrop, MannKind’s share price has shown strong recent momentum, with a 30 day share price return of 11.33% and a 90 day share price return of 72.37%, even though the year to date share price return is down 29.82% and the 1 year total shareholder return is 4.24%. If Afrezza’s pediatric progress has your attention, it could be a good time to broaden your watchlist and check out 39 healthcare AI stocks With MannKind now trading at $3.93 and sitting at a large discount to the average analyst price target, the key question is whether current levels still underappreciate Afrezza’s pediatric potential or whether the stock already reflects future growth. AdvertisementMost Popular Narrative: 48.2% Undervalued At a last close of $3.93 versus a narrative fair value of $7.59, MannKind is framed as heavily undervalued, with Afrezza and the inhaled pipeline doing most of the heavy lifting in that story.  Multiple late-stage pipeline programs (inhaled clofazimine for NTM and nintedanib DPI for IPF) are progressing toward key regulatory and clinical milestones, benefiting from expedited pathways and growing unmet need in chronic respiratory diseases, with the potential to significantly diversify and expand future revenues.  Read the complete narrative. Want to see how this expands beyond Afrezza and pediatrics? The narrative leans on ambitious revenue growth, margin expansion and a rich future earnings multiple. The underlying assumptions might surprise you. Result: Fair Value of $7.59 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this MannKind narrative can unravel quickly if Afrezza remains a niche product with limited adoption, or if core royalty streams face competitive or regulatory setbacks. Find out about the key risks to this MannKind narrative. Next Steps With investors split between Afrezza’s promise and the risks around adoption and royalties, it makes sense to move quickly and test the numbers for yourself, starting with the balance of 3 key rewards and 1 important warning sign Looking for more MannKind sized opportunities? If MannKind has reignited your interest in fresh ideas, do not stop here. Use the Simply Wall Street screener to hunt for the next stock that deserves your attention.  Target higher quality potential by reviewing companies trading at appealing valuations through the 43 high quality undervalued stocks. Strengthen your portfolio’s foundation by focusing on resilient businesses highlighted in the 67 resilient stocks with low risk scores. Spot future contenders early by working through the screener containing 19 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646544233","isCrawlerRequest":true}